StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Equities researchers at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Friday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 2.3 %

Brooklyn ImmunoTherapeutics stock opened at $0.52 on Friday. The firm’s fifty day moving average price is $1.03 and its two-hundred day moving average price is $1.57. The firm has a market capitalization of $30.59 million, a price-to-earnings ratio of -0.23 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.